Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia

Rhea-AI Summary

Relief Therapeutics (OTCQB: RLFTF) announced that its partner, NRx Pharmaceuticals, received an Emergency Use Authorization for aviptadil in Georgia for treating critical COVID-19 patients. The first doses are expected to arrive shortly. Relief’s RLF-100 (aviptadil) is in late-stage clinical testing in the U.S. for respiratory issues due to COVID-19. The company also established a collaboration with Acer Therapeutics to develop ACER-001 for Urea Cycle Disorders. Relief continues to diversify its pipeline following the acquisition of APR Applied Pharma Research.

Positive

• Emergency Use Authorization granted for aviptadil in Georgia, enhancing market presence.
• First doses of aviptadil arriving soon, indicating swift market entry.
• Collaboration with Acer Therapeutics for ACER-001 expands product pipeline.
• Recent acquisition of APR Applied Pharma Research diversifies development-stage programs.

Negative

• Dependence on collaboration partner NRx Pharmaceuticals for aviptadil's success.
• Uncertainty regarding FDA approval for their product in the U.S. and Europe remains.

GENEVA, SWITZERLAND / ACCESSWIRE / July 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP) (" NRx ") reported in a press release yesterday that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous aviptadil for the treatment of critical COVID-19.

NRx also reported that the first doses of aviptadil will arrive in the Nation of Georgia within 24 hours, and discussions are underway with the Ministry of Health to provide access to ZYESAMI(TM) to Georgians suffering with Critical COVID-19.

The related NRx press release can be accessed through the following link .

###

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100 ^TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisition of APR Applied Pharma Research brings a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com . Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer
Mail: contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
MC Services AG
Anne Hennecke
Tel.: +49 (0) 211-529-252-22
Mail: relief@mc-services.eu

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, and there can be no assurance regarding whether its collaboration partner's application for EUA will be approved by the FDA or that Relief will be successful in obtaining approval for the product in Europe or other territories. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/657384/Relief-Reports-that-its-US-Collaboration-Partner-has-Announced-Emergency-Use-Authorization-of-Aviptadil-in-Nation-of-Georgia

FAQ

What is the significance of the Emergency Use Authorization for aviptadil in Georgia?

The Emergency Use Authorization allows aviptadil to be used for critical COVID-19 treatment in Georgia, potentially boosting Relief Therapeutics' market presence.

How is Relief Therapeutics involved with NRx Pharmaceuticals?

Relief Therapeutics collaborates with NRx Pharmaceuticals for the development and commercialization of aviptadil.

What are the details of Relief's collaboration with Acer Therapeutics?

Relief has entered a Collaboration and License Agreement with Acer Therapeutics for the worldwide development of ACER-001, aimed at treating Urea Cycle Disorders.

What potential risks does Relief Therapeutics face regarding aviptadil's approval?

Relief faces risks related to regulatory approval from the FDA and other territories, impacting the commercialization of aviptadil.

When will aviptadil doses arrive in Georgia?

The first doses of aviptadil are expected to arrive in Georgia within 24 hours following the Emergency Use Authorization.